MYGN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Myriad Genetics, Inc.
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. for potential securities fraud violations. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 2025.
November 06, 2024 | 9:30 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities fraud after UnitedHealth announced it will stop covering the GeneSight test.
The investigation into potential securities fraud and the loss of coverage for GeneSight by UnitedHealth are significant negative developments for Myriad Genetics. These factors are likely to impact investor confidence and could lead to a decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100